UNICA IRIS Institutional Research Information System

ONALI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 62.708
NA - Nord America 2.770
AS - Asia 1.233
SA - Sud America 360
AF - Africa 38
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 67.118
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 62.035
US - Stati Uniti d'America 2.727
SG - Singapore 613
BR - Brasile 293
CN - Cina 287
SE - Svezia 251
VN - Vietnam 160
DE - Germania 115
FI - Finlandia 94
GB - Regno Unito 59
FR - Francia 36
HK - Hong Kong 31
AR - Argentina 30
PL - Polonia 24
KR - Corea 22
IN - India 21
CA - Canada 20
BD - Bangladesh 19
MX - Messico 17
ZA - Sudafrica 16
AT - Austria 14
NL - Olanda 14
ES - Italia 12
RU - Federazione Russa 10
TR - Turchia 10
EC - Ecuador 9
ID - Indonesia 9
IQ - Iraq 9
SA - Arabia Saudita 9
IE - Irlanda 7
JP - Giappone 7
PY - Paraguay 7
UA - Ucraina 7
UZ - Uzbekistan 7
KE - Kenya 6
MA - Marocco 6
PK - Pakistan 6
CL - Cile 5
CO - Colombia 5
GR - Grecia 5
CZ - Repubblica Ceca 4
IL - Israele 4
VE - Venezuela 4
AU - Australia 3
BE - Belgio 3
CH - Svizzera 3
EG - Egitto 3
HU - Ungheria 3
IR - Iran 3
KZ - Kazakistan 3
LU - Lussemburgo 3
BG - Bulgaria 2
EU - Europa 2
GY - Guiana 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
Totale 67.118
Salva come PNG Salva come JPEG
Città #
Cagliari 59.992
Uta 1.921
Ashburn 507
Fairfield 276
Singapore 276
Nyköping 204
Dallas 176
Boardman 166
Seattle 117
Wilmington 115
Chandler 105
Houston 104
Woodbridge 104
Cambridge 102
Helsinki 72
Santa Clara 72
Los Angeles 66
New York 64
Beijing 60
Boston 56
Dong Ket 52
Redwood City 46
Ho Chi Minh City 40
Hefei 39
Ann Arbor 35
Rome 32
Hong Kong 31
São Paulo 30
Buffalo 29
Munich 27
Redondo Beach 25
Hangzhou 24
Seoul 22
London 21
The Dalles 21
San Diego 20
Warsaw 20
Hanoi 19
Chicago 14
Frankfurt am Main 14
Turku 14
Atlanta 13
Shanghai 13
Belo Horizonte 12
Stockholm 12
Montreal 11
Nuremberg 11
Vienna 10
Jacksonville 9
Phoenix 9
Düsseldorf 8
Elk Grove Village 8
Lappeenranta 8
Mountain View 8
Nanjing 8
Rio de Janeiro 8
Salvador 8
Haiphong 7
Mexico City 7
Tashkent 7
Tokyo 7
Brooklyn 6
Denver 6
Johannesburg 6
Orem 6
Amsterdam 5
Chattanooga 5
Chennai 5
Columbus 5
Curitiba 5
Da Nang 5
Jiaxing 5
Manchester 5
Nairobi 5
Redmond 5
San Francisco 5
San Jose 5
Selargius 5
Wuhan 5
Ankara 4
Brasília 4
Brno 4
Council Bluffs 4
Dearborn 4
Jeddah 4
Kilburn 4
Limeira 4
Milan 4
New Delhi 4
Newark 4
Norwalk 4
Piscataway 4
Poplar 4
Recife 4
Ribeirão Preto 4
São Gonçalo 4
Tianjin 4
Toronto 4
Baghdad 3
Bogotá 3
Totale 65.490
Salva come PNG Salva come JPEG
Nome #
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 9.029
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.056
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.046
Colonic phenotype of the ileum in Crohn's disease: A prospective study before and after ileocolonic resection 1.965
Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: Relationship with colonic metaplasia 1.839
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.606
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 1.570
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.545
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 1.525
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.500
Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies 1.463
Cancer and immunomodulators in inflammatory bowel diseases 1.349
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.304
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.291
Adalimumab in active ulcerative colitis: A "real-life" observational study 1.185
Psoriasis phenotype in inflammatory bowel disease: A case-control prospective study 1.178
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's Disease 1.176
Endoscopic vs ultrasonographic findings related to Crohn's Disease recurrence: A prospective longitudinal study at 3 years 1.141
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.134
Anti-TNF-alpha treatments and obstructive symptoms in Crohn's Disease: A prospective study 1.099
The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases 1.057
A novel Smad7 genetic variant mapping on the genomic region targeted by Mongersen is associated with Crohn's disease 1.042
Female reproductive health and inflammatory bowel disease: A practice-based review 1.031
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.006
Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort 978
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 968
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 951
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 905
Measuring disease activity in Crohn's disease 905
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 905
Post-operative recurrence of Crohn's disease: A prospective study at 5 years 863
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial 862
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory bowel disease 847
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: Does blocking TNFα reduce colitis-associated colorectal carcinogenesis? 823
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies 799
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 797
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 789
Laparoscopic versus open ileo-colonic resection in crohn's disease: Short- and long-term results from a prospective longitudinal study 788
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 773
Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study 766
Cancer in Crohn's disease patients treated with infliximab: A long-term multicenter matched pair study 762
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 714
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 701
Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease 684
A family study of asymptomatic small bowel Crohn's disease 677
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 673
Immune system and gut microbiota senescence in elderly IBD patients 668
Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease 661
Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study 642
Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic 624
Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease 624
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease 611
Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: A prospective longitudinal study 573
Non-invasive techniques for assessing postoperative recurrence in Crohn's disease 536
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease 520
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 504
Severity of postoperative recurrence in Crohn's disease: Correlation between endoscopic and sonographic findings 468
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 399
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 387
Adherence to Mediterranean Diet and Diet Quality in Patients with Inflammatory Bowel Disease: A Single-Center, Observational, Case-Control Study 181
Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study 146
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus 138
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 107
Eosinophilic esophagitis in the "atopic march": dupilumab as an "umbrella" strategy for multiple coexisting atopic diseases 87
Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study 71
Interplay Between Depression and Inflammatory Bowel Disease: Shared Pathogenetic Mechanisms and Reciprocal Therapeutic Impacts-A Comprehensive Review 65
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 59
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD) 45
Corrigendum to "Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review" [Digestive and Liver Disease, Volume 56, Issue 1, January 2024, Pages 1-6] 37
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 33
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 31
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysis 28
Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic 11
Xanthine Oxidase-Dependent Activation of NLPR3 Inflammasome in Epithelial Cells Sustains Inflammation in Inflammatory Bowel Disease 7
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 1
Totale 67.331
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.555 0 0 0 0 0 313 107 248 78 120 126 563
2021/20225.351 220 367 306 237 377 498 188 351 646 570 934 657
2022/20238.657 544 1.071 1.175 529 725 1.276 454 733 461 543 738 408
2023/20247.747 399 352 293 492 633 1.533 953 824 395 528 635 710
2024/202539.273 15.737 12.943 4.297 2.031 939 1.434 1.084 58 225 180 133 212
2025/20262.316 333 167 646 589 342 239 0 0 0 0 0 0
Totale 67.331